MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Please visit our MS learning channel on YouTube, which provides hundreds of MS videos presented by MS Experts across the USA, from many of our recorded education programs. Archived here: www.youtube.com/msviewsandnews -- Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram

Important Resources for the MS community are found on the left side of this blog.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Monday, July 20, 2015

Study Evaluates Gilenya’s Impact on Central Autonomic Dysfunction In MS With Delayed Heart Rate

July 20th, 2015                     written by: Daniela Semedo, PhD

Fingolimod, also known by its brand name Gilenya, is an oral immunotherapy approved for the treatment of relapsing-remitting multiple sclerosis (MS). In a recent study published in the Journal PLOS One, a team of researchers found that the autonomic cardiovascular dysfunction in MS patients with delayed heart rate re-acceleration upon Fingolimod-initiation suggest that MS-related central autonomic lesions may compromise heart rate re-acceleration.
Fingolimod causes the heart rate to slow even in healthy persons and may also cause prolonged or more prominent heart rate slowing in some MS patients. Results from phase III clinical trials showed that Fingolimod caused bradycardia and serious cardiovascular adverse events, including atrioventricular blocks.
The European Medicines Agency (EMA) recommends that upon Fingolimod initiation, patients should have their heart rate monitored for at least six hours or if it is at the lowest value 6 hours following the first dose, extended monitoring for at least 2 more hours and until the heart rate increases again.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
 Keep CURRENT with MS Views and NewsOPT-IN here
.===================================

No comments: